Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

INVA

+ Watchlist+ Portfolio

Innoviva, Inc.

Regulated industrySells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$18.30
52-Week Range
$18.23 – $25.15
Market Cap
$1.31B
P/E (TTM)
7.83
EPS (TTM)
2.35
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.16
PEG Ratio
2.80
Return on Equity
18.02%
Return on Assets
7.29%
Gross Margin
76.97%
Operating Margin
39.49%
Profit Margin
44.13%
Current Ratio
15.44
Debt/Equity
0.29
Total Debt
$331.04M
Free Cash Flow
$121.16M
Revenue Growth
-1.60%
Earnings Growth
—
Enterprise Value
$1.05B

Market Snapshot

About

Innoviva, Inc. is a biopharmaceutical company with a portfolio of royalty streams from respiratory medications and an investment strategy focused on healthcare assets. The company receives royalties from RELVAR/BREO ELLIOTT and ANORO ELLIOTT, respiratory products partnered with GSK, which provide substantial recurring cash flows. Innoviva has diversified its business by making strategic investments in healthcare and life sciences companies through its subsidiary Innoviva Strategic Ventures. The company utilizes its royalty income to fund investments and return capital to shareholders while maintaining exposure to the pharmaceutical industry.